Skip to main content
SpringerLink
Log in

Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and Objective

Many patients with type 2 diabetes mellitus (T2DM) on insulin therapy have inadequate glycaemic control. In such cases, Dutch guidelines recommend unlimited up-titration of insulin, yet in practice many patients never reach their glycaemic target. Clinical evidence shows that dapagliflozin—a highly selective sodium–glucose cotransporter 2 inhibitor—meets a need for these patients, i.e. by reducing glycated haemoglobin levels and bodyweight. We estimated the cost effectiveness and cost utility of adding dapagliflozin to insulin compared with not adding dapagliflozin in patients with T2DM who have inadequate glycaemic control while on insulin.

Methods

The cost effectiveness of dapagliflozin was estimated using the Cardiff Diabetes Model, using direct comparative efficacy data from a randomized placebo-controlled trial (ClinicalTrials.gov identifier NCT00673231). In this trial, up-titration of insulin was allowed in case of severe glycaemic imbalance. Risk factor progression and the occurrence of future vascular events were estimated using the United Kingdom Prospective Diabetes Study 68 risk equations. Costs and utilities were derived from the literature. The analysis was conducted from the societal perspective, simulating the remaining lifetime of the patients.

Results

The overall incidence of macro- and microvascular complications was lower, and life expectancy was greater (19.43 versus 19.35 life-years [LYs]) in patients receiving dapagliflozin than in those not receiving dapagliflozin. Patients in the dapagliflozin arm obtained an incremental benefit of 0.42 quality-adjusted life-years (QALYs). The lifetime incremental cost per patient in the dapagliflozin arm was €2,293, resulting in an incremental cost-effectiveness ratio of €27,779 per LY gained and an incremental cost–utility ratio of €5,502 per QALY gained. Sensitivity and scenario analyses showed that the results were insensitive to variations in modelling assumptions and input variables.

Conclusion

Dapagliflozin in combination with insulin was estimated to be a cost-effective treatment option for patients with T2DM whose insulin treatment regimen does not provide adequate glycaemic control in a Dutch healthcare setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.

    Article  CAS  PubMed  Google Scholar 

  2. Nationaal Kompas Volksgezondheid, RIVM. http://www.nationaalkompas.nl Nationaal Kompas Volksgezondheid\Gezondheid en ziekte\Ziekten en aandoeningen\Endocriene, voedings- en stofwisselingsziekten en immuniteitsstoornissen\Diabetes mellitus; 2013 (Accessed 15 Aug 2013).

  3. Baan CA, van Baal PH, Jacobs-van der Bruggen MA, et al. Diabetes mellitus in the Netherlands: estimate of the current disease burden and prognosis for 2025. Ned Tijdschr Geneeskd. 2009;153:1052–8.

    PubMed  Google Scholar 

  4. Rutten GEHM, De Grauw WJC, Nijpels G, et al. The NHG guideline diabetes mellitus type 2. Huisarts Wet. 2013;56(10):512–25.

    Google Scholar 

  5. Gorter K, Van de Laar FA, Janssen PGH et al. Diabetes: glycaemic control in type 2 (drug treatments). Clinical Evid (Online). 2012. pii: 0609.

  6. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.

    Article  CAS  PubMed  Google Scholar 

  7. Carver C. Insulin treatment and the problem of weight gain in type 2 diabetes. Diabetes Educ. 2006;32:910–7.

    Article  PubMed  Google Scholar 

  8. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673–9.

    Article  PubMed  Google Scholar 

  9. Logtenberg SJ, Kleefstra N, Ubink-Veltmaat LJ, et al. Intensification of therapy and no increase in body mass index with longer disease duration in type 2 diabetes mellitus (ZODIAC-5). Fam Pract. 2007;24:529–31.

    Article  CAS  PubMed  Google Scholar 

  10. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520–6.

    Article  CAS  PubMed  Google Scholar 

  11. Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405–15.

    Article  PubMed  Google Scholar 

  12. McEwan P, Peters JR, Bergenheim K, et al. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin. 2006;22:121–9.

    Article  PubMed  Google Scholar 

  13. McEwan P, Evans M, Bergenheim K. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab. 2010;12:623–30.

    Article  CAS  PubMed  Google Scholar 

  14. McEwan P, Evans M, Kan H, et al. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. Diabetes Obes Metab. 2010;12:431–6.

    Article  CAS  PubMed  Google Scholar 

  15. The Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care. 2007;30:1638–46.

    Article  Google Scholar 

  16. Erhardt W, Bergenheim K, Duprat-Lomon I, et al. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis. Clin Drug Investig. 2012;32:189–202.

    Article  CAS  PubMed  Google Scholar 

  17. Granstrom O, Bergenheim K, McEwan P, et al. Cost-effectiveness of saxagliptin (Onglyza(R)) in type 2 diabetes in Sweden. Prim Care Diabetes. 2012;6:127–36.

    Article  PubMed  Google Scholar 

  18. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47:1747–59.

    Article  CAS  PubMed  Google Scholar 

  19. Wulffele MG, Kooy A, Lehert P, et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care. 2002;25:2133–40.

    Article  CAS  PubMed  Google Scholar 

  20. Wilding JP, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over two years. Diabetes Obes Metab. 2013;. doi:10.1111/dom.12187.

    Google Scholar 

  21. Bailey CJ, Wilding JP, Nauck M, et al. Sustained reductions in weight and HbA1c with dapagliflozin: long-term results from phase III clinical studies in type 2 diabetes. Diabetiologica. 2012;55 SUPPL. 1 (S295).

  22. Jonsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health. 2006;9:193–8.

    Article  PubMed  Google Scholar 

  23. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. [Geactualiseerde versie 2010]. 2010. College voor Zorgverzekeringen. http://www.cvz.nl.

  24. CBS Statline. statline.cbs.nl/statweb/ (Accessed 6 June 2012).

  25. Erdogan-Ciftci E, Koopmanschap MA. Productivity Costs using Frinction Cost method: New evidence using National Data. Value Health. ISPOR 14th Annual European Congress, vol. 14, Madrid; 2011, pp. A235–A236.

  26. Clarke P, Leal J, Kelman C, et al. Estimating the cost of complications of diabetes in Australia using administrative health-care data. Value Health. 2008;11:199–206.

    Article  PubMed  Google Scholar 

  27. Greving JP, Visseren FL, de Wit GA, et al. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ. 2011;342:d1672.

    Article  CAS  PubMed  Google Scholar 

  28. Isaaz K, Coudrot M, Sabry MH, et al. Return to work after acute ST-segment elevation myocardial infarction in the modern era of reperfusion by direct percutaneous coronary intervention. Arch Cardiovasc Dis. 2010;103:310–6.

    Article  PubMed  Google Scholar 

  29. Postmus D, Pari AA, Jaarsma T, et al. A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure. Am Heart J. 2011;162:1096–104.

    Article  PubMed  Google Scholar 

  30. Ericson L, Bergfeldt L, Bjorholt I. Atrial fibrillation: the cost of illness in Sweden. Eur J Health Econ. 2011;12:479–87.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Baeten SA, van Exel NJ, Dirks M, et al. Lifetime health effects and medical costs of integrated stroke services—a non-randomized controlled cluster-trial based life table approach. Cost Eff Resour Alloc. 2010;8:21.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Lindgren P, Glader EL, Jonsson B. Utility loss and indirect costs after stroke in Sweden. Eur J Cardiovasc Prev Rehabil. 2008;15:230–3.

    Article  PubMed  Google Scholar 

  33. Niessen LW, Dijkstra R, Hutubessy R, et al. Lifetime health effects and costs of diabetes treatment. Neth J Med. 2003;61:355–64.

    CAS  PubMed  Google Scholar 

  34. Fisher K, Hanspal RS, Marks L. Return to work after lower limb amputation. Int J Rehabil Res. 2003;26:51–6.

    Article  CAS  PubMed  Google Scholar 

  35. Keeffe JE. Costs of vision impairment: present and future issues. Expert Rev Pharmacoecon Outcomes Res. 2007;7:523–7.

    Article  PubMed  Google Scholar 

  36. van der Mei SF, Kuiper D, Groothoff JW, et al. Long-term health and work outcomes of renal transplantation and patterns of work status during the end-stage renal disease trajectory. J Occup Rehabil. 2011;21:325–34.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22:340–9.

    PubMed  Google Scholar 

  38. Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14:1–248.

    Google Scholar 

  39. Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22:1523–34.

    Article  PubMed  Google Scholar 

  40. Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Fam Pract. 1997;44:49–60.

    CAS  PubMed  Google Scholar 

  41. Lane S, Levy A, Sambrook J et al.. The impact on utilities of weight loss and weight gain among Canadian patients with type 2 diabetes. Value Health—ISPOR 17th Annual International Meeting, vol. 15, Washington DC; 2012, p. A183.

  42. Raad voor de Volksgezondheid en Zorg. Zinnige en Duurzame Zorg. 2006. Zoetermeer. http://www.rvz.net/publicaties/bekijk/zinnige-en-duurzame-zorg (Accessed 9 Oct 2013).

  43. Woehl A, Evans M, Tetlow AP, et al. Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom. Cardiovasc Diabetol. 2008;7:24.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5–26.

    Article  PubMed  Google Scholar 

  45. Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009;12:409–18.

    Article  PubMed  Google Scholar 

  46. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154:103–12.

    Article  PubMed  Google Scholar 

  47. Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:167–77.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was funded by Bristol-Myers Squibb and AstraZeneca. Heleen van Haalen and Rebecca Townsend are employees of AstraZeneca. Klas Bergenheim is an employee of AstraZeneca and owns stocks in AstraZeneca. Marjolein Pompen and Marina Roudaut are employees of Bristol-Myers Squibb. Phil McEwan has received unrestricted grants from both AstraZeneca and Bristol-Myers Squibb.

The authors thank all members of the strategic data review team for providing all necessary data and assistance for this research. In addition, we thank Pharmerit Europe for their technical support and IMS Health for their editorial support for this manuscript.

Author information

Authors and Affiliations

  1. Health Economics, AstraZeneca BV, P.O. Box 599, 2700 AN, Zoetermeer, The Netherlands

    Heleen G. M. van Haalen

  2. Bristol-Myers Squibb, Woerden, The Netherlands

    Marjolein Pompen

  3. AstraZeneca, Mölndal, Sweden

    Klas Bergenheim

  4. HEOR Ltd, Monmouth, UK

    Phil McEwan

  5. Centre for Health Economics, Swansea University, Swansea, UK

    Phil McEwan

  6. AstraZeneca, Brussels, Belgium

    Rebecca Townsend

  7. Health Economics and Outcome Research, Bristol-Myers Squibb, Rueil-Malmaison, France

    Marina Roudaut

Authors
  1. Heleen G. M. van Haalen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marjolein Pompen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Klas Bergenheim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Phil McEwan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rebecca Townsend
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marina Roudaut
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heleen G. M. van Haalen.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 681 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Haalen, H.G.M., Pompen, M., Bergenheim, K. et al. Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands. Clin Drug Investig 34, 135–146 (2014). https://doi.org/10.1007/s40261-013-0155-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-013-0155-0

Keywords

Search

Navigation